1. Home
  2. RKT vs ARGX Comparison

RKT vs ARGX Comparison

Compare RKT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket Companies Inc.

RKT

Rocket Companies Inc.

HOLD

Current Price

$19.49

Market Cap

54.1B

Sector

Finance

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$846.77

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RKT
ARGX
Founded
1985
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.1B
52.6B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
RKT
ARGX
Price
$19.49
$846.77
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$19.46
$971.89
AVG Volume (30 Days)
18.2M
300.0K
Earning Date
10-30-2025
10-30-2025
Dividend Yield
4.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
23.27
Revenue
$6,098,944,000.00
$3,683,281,000.00
Revenue This Year
$15.19
$91.44
Revenue Next Year
$71.65
$36.90
P/E Ratio
N/A
$33.78
Revenue Growth
41.68
92.98
52 Week Low
$10.06
$510.06
52 Week High
$22.56
$934.62

Technical Indicators

Market Signals
Indicator
RKT
ARGX
Relative Strength Index (RSI) 58.79 39.21
Support Level $18.71 $843.03
Resistance Level $19.63 $858.80
Average True Range (ATR) 0.58 15.73
MACD 0.00 -5.90
Stochastic Oscillator 77.27 21.13

Price Performance

Historical Comparison
RKT
ARGX

About RKT Rocket Companies Inc.

Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: